Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,818 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD37 in acute myeloid leukemia: a novel surface target for drug delivery.
Jeremy E, Artiga E, Elgamal S, Cheney C, Eicher D, Zalponik K, Orwick S, Mao C, Wasmuth R, Harrington B, Mustonen A, Beshay P, Halley P, Castro C, Williams K, Hing Z, Chen T, Lucas C, Vantangoli NJ, Lapalombella R, Grieselhuber N, Mo X, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin KT. Jeremy E, et al. Among authors: chen t. Blood Adv. 2025 Jan 14;9(1):1-14. doi: 10.1182/bloodadvances.2024013590. Blood Adv. 2025. PMID: 39348689
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC. McWilliams EM, et al. Among authors: chen t. Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684. Blood Adv. 2019. PMID: 30737226 Free PMC article.
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL, Harrington B, Truxall J, Wasmuth R, Prouty A, Sloan S, Lehman AM, Sampath D, Orlemans E, Baiocchi RA, Alinari L, Byrd JC, Woyach JA, Hertlein E. Chen TL, et al. J Hematol Oncol. 2021 Feb 24;14(1):36. doi: 10.1186/s13045-021-01039-9. J Hematol Oncol. 2021. PMID: 33627156 Free PMC article.
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Hoff FW, et al. Among authors: chen t. Blood Adv. 2024 Oct 22;8(20):5297-5305. doi: 10.1182/bloodadvances.2024013685. Blood Adv. 2024. PMID: 39110987 Free PMC article.
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Maddocks K, Hertlein E, Chen TL, Wagner AJ, Ling Y, Flynn J, Phelps M, Johnson AJ, Byrd JC, Jones JA. Maddocks K, et al. Leuk Lymphoma. 2016 Sep;57(9):2212-5. doi: 10.3109/10428194.2015.1129536. Epub 2016 Jan 14. Leuk Lymphoma. 2016. PMID: 26764527 Free PMC article. Clinical Trial. No abstract available.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. Cai SF, et al. Among authors: chen tl. Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563. Blood Adv. 2024. PMID: 37871309 Free PMC article.
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JC. Hertlein E, et al. PLoS One. 2013 Oct 9;8(10):e76607. doi: 10.1371/journal.pone.0076607. eCollection 2013. PLoS One. 2013. PMID: 24130782 Free PMC article.
32,818 results
You have reached the last available page of results. Please see the User Guide for more information.